X
[{"orgOrder":0,"company":"Ensem Therapeutics","sponsor":"GGV Capital","pharmaFlowCategory":"D","amount":"$67.0 million","upfrontCash":"Undisclosed","newsHeadline":"ENSEM Therapeutics, a CBC Group-Incubated Biopharma Company, Raises $67 Million in Series A Financing to Develop Small Molecule Medicines for Difficult-to-Drug Targets","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Ensem Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"D","amount":"$1,330.0 million","upfrontCash":"Undisclosed","newsHeadline":"BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Ensem Therapeutics","sponsor":"BeiGene","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ensem Therapeutics: Milestone Achieved with CDK2 Inhibitor for Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Ensem Therapeutics
Filters
Companies By Therapeutic Area
Details:
BG-68501, a small molecule cyclin-dependent kinase 2 (CDK2) inhibitor, which is being evaluated for the treatment of HR+/HER2 solid tumors including breast, ovarian, and Small Cell Lung Cancer.
Lead Product(s):
BG-68501,Fulvestrant
Therapeutic Area: Oncology
Product Name: BG-68501
Highest Development Status: Phase I
Product Type: Small molecule
Recipient:
BeiGene
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 12, 2024
Details:
Under the agreement, BeiGene will acquire an exclusive global license to an Investigational New Drug application-ready, ETX-197, an oral cyclin-dependent kinase 2 (CDK2) inhibitor.
Lead Product(s):
ETX-197
Therapeutic Area: Oncology
Product Name: ETX-197
Highest Development Status: IND Enabling
Product Type: Small molecule
Partner/Sponsor/Collaborator:
BeiGene
Deal Size: $1,330.0 million
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
November 21, 2023
Details:
Proceeds will be used to further advance the company's Kinetic Ensemble platform and accelerate R&D pipeline. Biomolecules such as proteins and RNAs are in constant motion, with an ensemble of conformations that govern their functions.
Lead Product(s):
Undisclosed
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Discovery
Product Type: Small molecule
Partner/Sponsor/Collaborator:
GGV Capital
Deal Size: $67.0 million
Upfront Cash: Undisclosed
Deal Type: Series A Financing
April 06, 2022